Evidence map›Paper›PMID 38177656›Full record

ArticleScientific reports2024

Extensive antibody search with whole spectrum black-box optimization.

Andrejs Tučs, Tomoyuki Ito, Yoichi Kurumida, Sakiya Kawada, Hikaru Nakazawa, Yutaka Saito, Mitsuo Umetsu, Koji Tsuda

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrejs Tučs *Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Tomoyuki Ito *Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.
Yoichi KurumidaArtificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.
Sakiya KawadaDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.
Hikaru NakazawaDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.
Yutaka SaitoGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Mitsuo UmetsuDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan. mitsuo@tohoku.ac.jp.
Koji TsudaGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan. tsuda@k.u-tokyo.ac.jp.

Funding

Japan Science and Technology Agency JPMJER1903New Energy and Industrial Technology Development Organization Development of the Key Technologies for the Next-Generation Artificial Intelligence/Robots
6 · The paper itself

Abstract

In designing functional biological sequences with machine learning, the activity predictor tends to be inaccurate due to shortage of data. Top ranked sequences are thus unlikely to contain effective ones. This paper proposes to take prediction stability into account to provide domain experts with a reasonable list of sequences to choose from. In our approach, multiple prediction models are trained by subsampling the training set and the multi-objective optimization problem, where one objective is the average activity and the other is the standard deviation, is solved. The Pareto front represents a list of sequences with the whole spectrum of activity and stability. Using this method, we designed VHH (Variable domain of Heavy chain of Heavy chain) antibodies based on the dataset obtained from deep mutational screening. To solve multi-objective optimization, we employed our sequence design software MOQA that uses quantum annealing. By applying several selection criteria to 19,778 designed sequences, five sequences were selected for wet-lab validation. One sequence, 16 mutations away from the closest training sequence, was successfully expressed and found to possess desired binding specificity. Our whole spectrum approach provides a balanced way of dealing with the prediction uncertainty, and can possibly be applied to extensive search of functional sequences.

Indexed as

AntibodiesProtein EngineeringMachine LearningAntibodies

Identifiers

PMID38177656
PMCPMC10767033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.